IMO-2055: Final Phase II data

Final data from an open-label, U.S. Phase II trial in 89 patients showed that IMO-2055 led to 52 cases of stable disease and produced 2 partial responses, both in the 0.64 mg/kg cohort. Treatment-naïv...